Skip to main content
Premium Trial:

Request an Annual Quote

Ontario Genomics Institute to Invest $87K in Amorfix to Support Development of Alzheimers Dx

NEW YORK, Jan. 31 (GenomeWeb News) - The Ontario Genomics Institute will invest Can$100,000 (US$87,465) in Amorfix Life Sciences to support development of a blood test for Alzheimer's disease, the organizations said today.


OGI has agreed to invest Can$50,000 in the company, for which it will receive 100,000 common shares and 50,000 warrants to purchase shares for $.90 for a term of two years.


Upon the achievement of a "defined research milestone," OGI will invest another Can$50,000 at market price and receive a one-half warrant for each share purchased to purchase a share at the then market price within two years.


Amorfix is developing an Alzheimer's diagnostic called EP-AD that is based on its Epitope Protection technology. The company said that its technology can detect aggregated misfolded proteins in blood that are associated with Alzheimers disease but difficult to identify with traditional methods.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.